Member Info for wolfi

To get regulatory approval and planning permissions and the build time to construct a purpose built quarantine unit will be in the region of 18 months to 2 years, plus at current estimates the cost of £40 million. Also where do you think Oxford will get the staff with decades of experience running challenge trials.

I know CF has previously stated on a number of occasions that Invesco were happy to hold, but sometimes circumstances change.

Bear - when the RNS landed that stated OO and quotient had entered into an agreement over antibody testing on 11th May the sp stood at 12.4p, so has risen less than a penny in the 3 months since, so yeh no big deal.

Executive Summary
Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.

hTTps://scrip.pharmaintelligence.informa.com/SC141666/CodagenixSerum-Join-Fray-To-Develop-SARSCoV2-Vaccine

Maurice Treacy talks about Genomic data and it's value to open orphan, starts to cover it in depth from about 13 minutes in.

hTTps://www.youtube.com/watch?v=XrT6SBVa5F0

Swapleber - The Israel company Biondvax which also has a universal flu vaccine is listed on Nasdaq with mkt cap $250 million usd, they are all ready in phase 3 and due to report in 6 months time. It appears though that they are a 0ne trick pony with nothing else in their stable.

Latest CF interview, i believe recorded yesterday;

hTTps://www.youtube.com/watch?v=SkzUP8n_d08

come on guys , knock it on the head please.

Rudey - bear in mind that CF stated that the profit on the challenge studies was circa 40%, not sure if that is gross or net though.

Luckyball - Might be worth letting Cathal know, contact, Cathal.Friel@openorphan.com

Can i ask you why you think it would be ?

malteaser - looks like Youregene are well behind everyone else, it's a antigen test is it not ?

Potential Mossie vaccine would no doubt have the Bill and Melinda Gates Foundation and the Open Philanthropy Project interested..

Last contract we signed we didn't know who it was with either except that it was a US Biotech company, we did get info on contract value though. I assume that this time there was no info on contract value as they are signing multipile contracts which may have differing terms.

barwickman - has obviously sold or he needs to go to specsavers.

Probably because it is commercially sensitive info, especially when they are signing many of these contracts with various major pharma companies, terms may differ !

Northseatiger1 - since when has Venn been one of the top pharmaceutical companies in the world.

Analyst Q&A with Quotient today , hvivo mentioned lots , possibility of another covid test being available.

We are discussing with clinicians variations to the test. I think first and foremost, the actual performance of the test is important. We have seen with many alternatives that they do not perform as promised than in realized, yes. And sometimes they need like two weeks to show the antibodies, probably because they are stronger on IgG and weaker on IgM, I don't know even I covered IgM. Some of them took even up to four weeks to get up to performance. So ours is only seven days after positive PCR test, and you have a high performing test.

So the performance should not softer with modifications. So modifications, we are currently looking at working on. And discussing with clinicians is a semi-quantitative microarray. We are also looking into -- they had a value of having IgG and IgM separated what is the clinical value in terms of personalized treatment afterwards or how they proceed with this case. So all this is up and running in parallel. So it could very well be that we have a second COVID-19 test very soon or a replacement with further attribute. But we only make this investment and development if the market is valuing this additional information, which we are classifying right now.

hTTps://www.nasdaq.com/articles/quotient-limited-qtnt-q4-2020-earnings-call-transcript-2020-06-10

Yet in the British medical journal it is stated

Roche’s Anti-SARS-CoV-2 serology assay was tested between 5 and 7 May by the PHE diagnostic support group,2 which used 93 serum samples from convalescent patients and 472 negative samples. The team reported that all negative samples tested negative, giving a specificity of 100%, while the overall sensitivity was 83.87%, rising to 87.0% at 14 days after onset of symptoms, 87.7% 21 days after, and 100% more than 40 days after.

Abbott’s SARS-CoV-2 IgG kit was tested between 4 and 7 May,3 with 96 samples from convalescent patients and 759 negative samples. The assay was found to be 99.63% specific, with a sensitivity of 93.90% at 14 days after symptom onset, dropping to 93.40% at 21 days and 87.5% at 40 days.
https://www.bmj.com/content/369/bmj.m2066

Some good Q&A on our new antibody testing for new investors.

hTTps://www.share-talk.com/overview-facts-about-hvivo-covid-clear-faq/#gs.821q4l

What i didn't know was that our test can detect antibodies from 9 days post symptoms whilst Roche's test takes upto 42 days post symptoms.